<SEC-DOCUMENT>0001193125-19-199441.txt : 20190723
<SEC-HEADER>0001193125-19-199441.hdr.sgml : 20190723
<ACCEPTANCE-DATETIME>20190723080558
ACCESSION NUMBER:		0001193125-19-199441
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190723
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190723
DATE AS OF CHANGE:		20190723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		19966814

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d780093d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): July&nbsp;23, 2019 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38359</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-3305277</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston Street, 12th Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02116</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area
<FONT STYLE="white-space:nowrap">code:&nbsp;(857)&nbsp;315-5521</FONT> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $0.0001 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>TORC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;&nbsp;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2019, resTORbio, Inc. (the &#147;Company&#148;) issued a press release titled &#147;resTORbio Announces Early Completion of Enrollment of
Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness.&#148; A copy of the press release is attached as Exhibit 99.1 to this Form <FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d780093dex991.htm">Press release issued by resTORbio, Inc. on July&nbsp;23, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;23, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>resTORbio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chen Schor</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d780093dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g780093page3a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically
Symptomatic Respiratory Illness </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020
&#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in <FONT
STYLE="white-space:nowrap">mid-2020</FONT> &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON, MA, July</B><B></B><B>&nbsp;23, 2019</B> &#150; resTORbio, Inc. (Nasdaq: TORC) today
announced that it has completed patient enrollment of the Phase 3 PROTECTOR 1 trial, ahead of previously announced clinical timelines, with 1,024 patients randomized. PROTECTOR 1 is the first of two global Phase 3 clinical trials evaluating the
potential of RTB101 to improve the immune function of patients aged 65 and older and thereby decrease the incidence of illness associated with respiratory tract infections (RTIs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased with the rapid pace of enrollment of PROTECTOR 1, which now puts us on a timeline to potentially announce topline data from this
Phase 3 study by early first quarter of 2020,&#148; said Chen Schor, <FONT STYLE="white-space:nowrap">co-founder,</FONT> president and chief executive officer of resTORbio. &#147;This is a significant milestone for the company, and we believe it
underscores the strong interest of clinicians and patients in the potential clinical benefits of RTB101. We believe that RTB101 has the potential to be a paradigm-shifting treatment to reduce the incidence of illness associated with RTIs in older
adults. RTIs are the fourth leading cause of hospitalization and seventh leading cause of death in people 65 years of age and older in the U.S. The majority of RTIs are caused by many different types of viruses, most of which lack effective
treatment.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The design of the Phase 3 PROTECTOR program is based on results from two Phase 2 trials and incorporates feedback from both the U.S.
Food and Drug Administration and the&nbsp;European Medicines Agency. In two Phase 2 clinical trials that enrolled more than 900 older adults, RTB101 was observed to improve immune function by upregulation of pan antiviral gene expression and to
reduce the incidence of RTIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Phase 3 PROTECTOR Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 3 PROTECTOR program includes two randomized, double-blind, placebo-controlled clinical trials: PROTECTOR 1 and PROTECTOR 2. The program was designed
to evaluate the safety and efficacy of RTB101 10mg given orally once daily for 16 weeks during winter cold and flu season in adults 65 years of age and older, excluding current smokers and chronic obstructive pulmonary disease patients. The primary
endpoint of both trials is the reduction in the percentage of patients with clinically symptomatic respiratory illness, defined as illness associated with RTIs, based on prespecified diagnostic criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PROTECTOR 1, currently underway in the southern hemisphere, has completed enrollment of 1,024 patients. PROTECTOR 2 is expected to be initiated in the
northern hemisphere in the fourth quarter of 2019 and to enroll approximately 1,600 patients. Based on current enrollment expectations for PROTECTOR 2, resTORbio anticipates announcing topline data from this trial in
<FONT STYLE="white-space:nowrap">mid-2020.</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Respiratory Tract Infections in Older Adults </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the aging process, the immune system weakens and becomes less effective at detecting and fighting infections such as RTIs. As a result, RTIs are
more likely to be of greater severity, prolonged duration, and are more likely to be associated with medical complications in people 65 years of age and older compared to younger adults. In the U.S., RTIs are the fourth leading cause of
hospitalization and seventh leading cause of death in people 65 years of age and older. Given that the majority of RTIs are caused by many different types of viruses, most of which lack effective therapies, there remains a significant unmet medical
need for an immunotherapy that enhances the ability of the immune system to fight multiple viruses to reduce illness associated with RTIs in older adults. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About RTB101 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RTB101 is an oral, selective, and potent
TORC1 inhibitor product candidate. TORC1 inhibition has been shown to be of therapeutic benefit in multiple aging-related conditions in preclinical species including immunosenescence (aging-related decline in immune function). In two Phase 2
clinical trials enrolling over 900 elderly people, RTB101 was observed to improve immune function by upregulation of <FONT STYLE="white-space:nowrap">pan-antiviral</FONT> gene expression and to reduce the incidence of RTIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About resTORbio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. is a clinical-stage
biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. resTORbio&#146;s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to
the decline in function of multiple organ systems, including immune, neurologic and cardiac function. Learn more about resTORbio, Inc. at www.resTORbio.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors are cautioned that statements in this press release, which are not strictly historical statements, including, without
limitation, express or implied statements or guidance regarding our proposed timing, enrollment, trial design and anticipated results for our PROTECTOR Phase 3 clinical program of RTB101, our future plans to develop RTB101 alone or in combination
with rapalogs, such as everolimus or sirolimus, including the therapeutic potential and clinical benefits thereof and the potential patient populations that may be addressed by our product candidates, our ongoing and future clinical trials for
RTB101, including the timing of the initiation and anticipated results of these trials, and our ability to replicate results achieved in our clinical trials in any future trials, constitute forward-looking statements identified by words like
&#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those
anticipated, including, without limitation, risks associated with: our PROTECTOR Phase 3 program; our planned Phase 3 clinical trials in RTIs and/or development of RTB101, either alone or in combination with a rapalog, such as everolimus or
sirolimus; uncertainties related to the results of our clinical trials predictive of future results in connection with future trials, including our Phase 3 clinical trials; the timing and outcome of our planned interactions with regulatory
authorities; and obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled &#147;Risk Factors&#148; in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
filed by resTORbio, Inc. with the&nbsp;Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the&nbsp;Securities and Exchange Commission.&nbsp;In
addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lora Pike </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lpike@restorbio.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amir Khan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosector 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-849-9496</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amir.khan@syneoshealth.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g780093page3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g780093page3a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MJ=IJEN)K28.O<="I]".U<LX2@[2.R%2-17BRW4%A0 4 % !0 4 % !0 4 %
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M&$IPE3NT,\8&VTK2UL[*". W;?O/+7&57_ZY%/#<U2?-)WL&*Y:<.6*M<X0
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M2M6M=8LA=6K$KG#*>"I]#0!"=:C'B)='\EMYB\SS,C'TQ0!;O[^VTRS>ZNI
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MP+I4OVF34I$*Q!2D>?XB>I%9XNHK<B-<%2=^=EEK2&[^)<GG(&$4"R*#TW
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MS0 M $#V-I))YCVL+O\ WFC!/YT 3@8& ,"@!: "@ H * "@ H * "@ H *
D"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
